Table 1

Association between TaqI genotype and breast cancer risk according to breast cancer risk factors (All tests for statistical significance were two-sided)

Genotype (no. Cases/no. Controls)P interaction
TT (157/147)Tt (184/181)tt (62/55)
ORa(95% CI)ORa(95% CI)ORa(95% CI)
All subjects1.00(ref)1.06(0.77–1.48)1.15(0.72–1.82)
Disease stageb
 Local1.00(ref)1.10(0.76–1.59)1.31(0.78–2.18)
 Regional/distant1.00(ref)0.97(0.61–1.56)0.75(0.35–1.59)0.07
Menopausal status
 Premenopausal1.00(ref)1.04(0.59–1.86)1.51(0.67–3.41)
 Postmenopausal1.00(ref)1.07(0.47–1.62)0.85(0.47–1.54)0.21
Family history
 No1.00(ref)1.03(0.98–1.79)1.43(0.74–2.06)
 Yes1.43(0.73–2.80)1.23(0.49–3.10)0.68(0.21–2.26)0.68
Multivitamin use
 Never1.00(ref)0.96(0.46–2.01)1.09(0.40–2.98)
 Former1.13(0.58–2.22)1.27(0.51–3.17)1.66(0.46–5.98)
 Current1.15(0.60–2.24)0.96(0.39–2.35)0.78(0.23–2.66)0.54
Postmenopausal hormone usec
 Never1.00(ref)1.11(0.72–1.71)1.66(0.93–2.99)
 Former/current1.09(0.65–1.82)0.90(0.46–1.75)0.35(0.13–0.93)0.10
Body Mass Index (kg/m2)c
 <241.00(ref)1.77(0.84–3.67)1.52(0.56–4.11)
 24–273.23(1.38–7.58)0.29(0.09–0.90)0.23(0.05–0.98)
 27+1.76(0.84–3.67)0.67(0.25–1.82)0.70(0.17–2.96)0.34
  • a Adjusted for age, family history of breast cancer, body mass index, age at first birth, hormone replacement therapy, and menopausal status.

  • b Polytomous logistic regression model adjusted for age, family history of breast cancer, body mass index, age at first birth, hormone replacement therapy, and menopausal status.

  • c Postmenopausal women only.